From tracking LIMRA quarterly sales data alongside reinsurer mortality studies since 2023, a pattern has become clear: the same accelerated underwriting programs powering the industry’s premium growth are also producing a systematic gap between priced mortality and experienced mortality. The Q1 2026 numbers sharpen that tension into a first-order pricing question.
LIMRA released its Q1 2026 U.S. Individual Life Insurance Sales Survey on May 6, 2026, reporting total new annualized premium plus excess of $4.5 billion, a 10% year-over-year increase. IUL led growth with $1.1 billion in new premium (up 14%), while whole life policy count surged 13%. This follows a record $17.5 billion in full-year 2025 new premium. The volume is welcome. The pricing question is whether the mortality assumptions embedded in that volume are adequate.
The Volume Picture: Q1 2026 by Product
Every major product line except fixed universal life posted positive growth in Q1 2026. The breadth of growth matters for the AUW pricing discussion because accelerated underwriting touches multiple product lines, each with different mortality margin profiles.
| Product | Q1 2026 Premium | YoY Growth | Market Share |
|---|---|---|---|
| Whole Life | $1.6B | +9% | 36% |
| Indexed Universal Life (IUL) | $1.1B | +14% | 25% |
| Term Life | $788M | +9% | 18% |
| Variable Universal Life (VUL) | $729M | +12% | 16% |
| Fixed Universal Life | $221M | -6% | 5% |
Source: LIMRA U.S. Individual Life Insurance Sales Survey, Q1 2026.
The combined IUL and VUL share now stands at 41%, up from roughly 30% in 2019. This shift matters for AUW mortality slippage because indexed and variable products amplify the financial impact of mortality misestimation. IUL pricing depends on an option budget that must absorb both index crediting costs and mortality charges; a 15% mortality load shortfall eats directly into the spread available for option purchases. VUL separate account structures face a similar dynamic through cost-of-insurance rate corridors.
What Accelerated Underwriting Mortality Slippage Actually Measures
Mortality slippage is the ratio of expected mortality under traditional full underwriting to expected mortality under the accelerated process. A slippage ratio of 1.15 (or 15%) means that the AUW population carries 15% higher mortality than a traditionally underwritten population at the same rate class, because the accelerated process admits applicants that traditional methods would have caught and either declined or rated.
Swiss Re’s 2026 analysis estimated that industry-wide AUW mortality slippage averages 15%, with individual carrier programs ranging from 5% to over 30%. That range is wide enough to be the difference between a profitable block and a reserve-strengthening event five years into a program’s life.
The Confusion-Matrix Framework
The standard approach to estimating AUW slippage runs a sample of applicants through both the traditional full-underwriting process and the accelerated process simultaneously, then maps outcomes into four cells:
| Traditional UW: Accept | Traditional UW: Decline/Rate | |
|---|---|---|
| AUW: Accept | True Pass (correctly accepted by both) | False Pass (accepted by AUW, caught by traditional) |
| AUW: Decline/Rate | False Decline (rejected by AUW, accepted by traditional) | True Decline (correctly rejected by both) |
The false-pass cell is the primary source of mortality slippage. These are applicants who would have been declined, rated, or reclassified under traditional underwriting but were accepted at standard rates through the accelerated pathway. The false-decline cell represents opportunity cost: applicants the AUW program rejected conservatively who would have been accepted traditionally.
The slippage ratio is then calculated as:
Slippage Ratio = Expected Mortality (Traditional UW Population) / Expected Mortality (AUW Population)
Values below 1.0 indicate the AUW process is more restrictive than traditional methods (rare in practice). Values above 1.0 indicate excess mortality leaking through the accelerated pathway.
RGA’s Warning: The Hidden Assumptions Behind the Range
In April 2026, RGA published research that identified the single largest assumption driving the 5%-to-30% slippage range: the mortality assigned to false-pass cases. The question is straightforward but consequential. When an applicant is accepted by AUW but would have been declined by traditional underwriting, what mortality do you assign to that applicant?
If you assume false-pass cases carry the same mortality as all traditionally declined applicants, slippage estimates come in high. If you assume they carry an intermediate mortality between standard and declined populations, estimates drop sharply. RGA’s research demonstrated that “reasonable changes in those assumptions can produce a wide range of outcomes,” and that much of the published variation in slippage estimates reflects this single assumption rather than genuine differences in AUW program quality.
RGA also emphasized the importance of separating two distinct evaluation dimensions. Risk selection assessment asks whether the AUW program correctly identifies insurable versus uninsurable lives. Risk classification evaluation asks whether accepted lives are placed in the correct rate class. Conflating the two inflates perceived slippage because classification boundary shifts (moving a preferred-plus applicant to preferred, for instance) get misattributed to selection failures.
Face Amount and Age Gradients
RGA’s data reveals that slippage is not uniform across the book. Two gradients stand out for pricing actuaries:
Face-amount gradient: Policies above $500,000 show lower mortality slippage than smaller face amounts. The likely explanation is that higher face amounts trigger more data pulls in the AUW decision engine (prescription history, MIB hits, MVR checks) and are more likely to receive a reflexive full-underwriting referral when red flags appear. Smaller face amounts, where carriers compete aggressively on speed and convenience, receive lighter scrutiny.
Issue-age gradient: Ages 18 to 30 show higher slippage than the 31 to 40 cohort. Younger applicants have thinner medical and prescription histories, giving AUW algorithms less signal to work with. The irony is that these applicants also represent the longest-duration exposure, so mortality mispricing at young issue ages compounds over decades.
Both gradients argue for tiered mortality loading rather than a flat AUW surcharge, with higher loads on smaller face bands and younger issue ages where the data signal is weakest.
The GLP-1 Complication
Any discussion of life insurance mortality assumptions in 2026 must address GLP-1 receptor agonists. Clinical trial data from the SELECT trial showed a 19% to 20% reduction in all-cause mortality for participants on semaglutide versus placebo. If those results translate to real-world insured populations, base mortality tables could improve materially over the next decade.
The problem is adherence. Real-world adherence rates for GLP-1 medications sit below 40% overall and under 30% for ages 30 to 40. That creates an asymmetric pricing risk: if a carrier aggressively improves mortality assumptions based on GLP-1 clinical data but real-world adherence does not improve, the pricing error flows directly to the bottom line. For AUW programs specifically, GLP-1 usage is observable through prescription data pulls, but discontinuation is not, creating a snapshot-in-time problem where an applicant’s GLP-1 status at issue may not persist through the policy duration.
Pricing actuaries should treat GLP-1 mortality improvement as a potential future offset to AUW slippage rather than a current assumption change. The credibility of the clinical data is high, but the gap between clinical trial populations and insured populations under real-world adherence conditions is too wide to price aggressively today.
Monitoring AUW Program Performance: SCOR’s Benchmarking Framework
SCOR has published a benchmarking framework for ongoing AUW program monitoring that goes beyond static slippage estimation. The key performance indicators include:
- Slippage ratio trend: Tracking the confusion-matrix slippage estimate over rolling 12-month windows to detect drift in AUW model performance as the applicant mix evolves.
- Approval-rate drift: Monitoring the percentage of applications that pass through the accelerated pathway without referral. An increasing approval rate may signal loosening thresholds, which would increase false-pass volume.
- Experience-to-expected (A/E) ratios stratified by underwriting pathway: Splitting actual-to-expected mortality comparisons between the AUW book and the traditionally underwritten book to isolate pathway-specific mortality performance.
- Reflexive referral hit rate: Tracking the proportion of AUW applications that trigger a reflexive review (additional data pulls or escalation to full underwriting) and the ultimate disposition of those referrals.
The value of SCOR’s approach is that it treats AUW monitoring as an ongoing calibration problem rather than a one-time study. Slippage is not a fixed number; it evolves as AUW models are retrained, as the applicant population shifts, and as external data sources change coverage or scoring methodology.
Constructing a Credibility-Graded Mortality Load
The practical pricing question is how to translate a slippage estimate into a mortality load that converges toward actual program experience as credible data accumulates. The Bühlmann credibility framework provides a clean solution.
For a new AUW program with limited experience, the mortality load begins at the estimated slippage factor. If Swiss Re’s 15% industry average is the starting prior, the initial AUW mortality assumption is set at 115% of the base mortality table for the applicable rate class.
As the program generates its own mortality experience, the credibility-weighted mortality load is:
AUW Mortality Load = Z × (A/E from AUW Experience) + (1 - Z) × (Prior Slippage Estimate)
where Z = n / (n + k)
In this formulation, n is the volume of AUW mortality experience (measured in expected deaths or exposure years), and k is a parameter calibrated to the variance of AUW mortality experience relative to the prior distribution. A high-variance AUW program (one where A/E ratios fluctuate significantly across quarterly windows) produces a larger k, which slows the convergence from the prior toward actual experience. A stable AUW program with consistent A/E ratios produces a smaller k, allowing faster convergence.
In practice, pricing actuaries should stratify this framework by the dimensions where slippage varies most:
- Face band: Separate credibility calculations for policies below $250K, $250K to $500K, and above $500K, reflecting the face-amount slippage gradient.
- Issue age: Separate calculations for ages 18 to 30, 31 to 50, and 51+, reflecting the data-signal gradient.
- Underwriting pathway: Maintain distinct A/E tracking for fully accelerated policies versus those that received a reflexive review before acceptance.
As the AUW book matures and each cell accumulates credible volume, k can be recalibrated and the mortality table converges toward a program-specific basis that reflects the carrier’s actual AUW population rather than the industry-wide prior.
Why This Matters for Pricing Actuaries
The interaction between AUW slippage and product complexity is the key risk. A 15% mortality overrun on a term life block produces a quantifiable hit to loss ratios, but the product’s simple structure limits second-order effects. The same 15% overrun on an IUL block compounds through the option budget: higher-than-expected mortality charges reduce the spread available for index crediting, which either compresses carrier margins or forces a reduction in illustrated rates that damages competitiveness. With IUL and VUL now commanding 41% of the market, the financial leverage of mortality misestimation has increased materially.
For pricing actuaries building or refreshing AUW mortality assumptions in 2026, the framework distills to three principles. First, start with the confusion-matrix methodology but scrutinize the false-pass mortality assumption, because that single parameter drives most of the variation in published slippage estimates. Second, load by face band and issue age rather than applying a flat surcharge, because the data shows that slippage concentrates in smaller policies and younger applicants. Third, use a credibility-graded structure that begins conservatively and converges toward actual program experience, so that the mortality assumption improves as the book matures without requiring actuaries to guess at the steady-state slippage level upfront.
The Q1 2026 sales data confirms that AUW-powered growth is not slowing. The pricing question is whether mortality assumptions are keeping pace with volume. For carriers where they are not, the gap between priced and experienced mortality will widen with every quarter of record sales.